Laddar populära aktier...
Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market exp...
Bolagsverket har idag registrerat fusionen mellan Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") ("Fusione...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggjorde den 28 juni 2024 att Bolaget ingått ett samgåendeavtal med PRS1 A...
Magle Chemoswed Holding AB ("Magle Group") har idag hållit extra bolagsstämma.
Styrelsen för Magle Chemoswed Holding AB ("Magle Group") har idag, med stöd av bemyndigandet från årsstämman den 25 april 2024, beslutat att...
In an ambitious move to transform wound care, Magle Chemoswed and I2Pure have unveiled a joint venture, marrying I2Pure's groundbreaking mol...
Bolagsverket har idag lämnat tillstånd till Magle Chemoswed Holding AB ("Magle Group") att verkställa fusionsplanen avseende fusionen mellan...
Aktieägarna i Magle Chemoswed Holding AB (publ), org.
The company aims to establish itself as a leader in life-changing healthcare innovations.
BioStock intervjuar Magle Group om bolagets rapport för det första halvåret 2024 och dyker in bland annat in i bolagets tillväxt, den ökade ...
Magle Group's Q2 report highlights organic sales growth and future market expansion with startegic mergers
Idag meddelar Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") att fusionsdokumentet avseende fusionen ("Fusionen") med Amniotics ...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har idag tillträtt aktierna i förvärvet av pK Biotech ApS ("pK Biotech") och dess...
Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har ingått ett samgåendeavtal med PRS1 ApS (”Säljaren”) avseende förvärv av samtl...
Flexibiliteten hos ett mindre företag och bredden hos de största bolagen – så beskriver Magle Group sitt erbjudande.
Magle Group fokuserar på fortsatt tillväxt genom breddning av CDMO-erbjudandet och utveckling av fler medicinska produkter baserade på Degra...
Magle Chemoswed Holding AB ("Magle Group") har ingått ett bindande avtal att förvärva samtliga aktier i pK Biotech ApS och dess dotterbolag ...
Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") (tillsammans "Bolagen") meddelar idag, den 30 maj 2024, att...
Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle" eller "Magle Group") (STO: MAGLE), ett ledande CDMO-företag (Contract D...
Idag, den 25 april 2024, hölls årsstämma i Magle Chemoswed Holding AB (publ).
Today, on 18 April 2024, Magle Chemoswed Holding AB (publ) has published its interim report for Q1, 2024.
Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle Group") ett rekommenderat offentligt uppköpserbjudande till aktieägarna ...
Magle Chemoswed Holding's Annual Report for 2023 has been published on the Group’s website as of today.
The Board of Directors' of Magle Chemoswed Holding AB (publ) (“Magle Group” or the “Company”) assessment of the Company's dividend capacity ...
Magle Chemoswed Holding AB[1] ("Magle" eller "Magle Group") offentliggör härmed ett rekommenderat offentligt uppköpserbjudande till aktieäga...
Magle Chemoswed Holding AB (publ), an established innovation-led healthcare group with proven growth through risk diversification and focus ...
Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the establishment of a collaboration and exclusive worldwide...
Today, on 18 Julyl 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q2 2023.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has filed a new patent application for its ...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company’s CEO Justin Pierace purhases 172,800 Magle...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the presentation of data from the company’s first post-marke...
Idag, den 26 april 2023, hölls årsstämma i Magle Chemoswed Holding AB (publ).
Today, on 19 April 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q1 2023.
Magle Chemoswed Holding's Annual Report for 2022 has been published on the Group’s website as of today.
Aktieägarna i Magle Chemoswed Holding AB (publ), org nr.
Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus ...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that AXXO® Woundgel has received regulatory approval in Kuwa...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that Embocept® S has received regulatory approval in Argenti...
Today, on 9 November 2022, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2022.
Magle Chemoswed Holding AB (publ) will publish its interim report for Q3 2022 on Wednesday 9 November 2022 at 08:30 CET.
Magle Chemoswed Holding AB (publ) hereby announces that the company has entered into an agreement with Vator Securities AB (“Vator Securitie...
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the appointment of Helena Ossmer Thedius as Chief Marketing ...
Magle Chemoswed Holding Reports Financial Results For First Half year 2022
Julia Kamber Rouhi, a deputy member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Bo...
Magle Chemoswed Holding AB (publ) will publish its interim report for Q2 2022 on Wednesday 17 August 2022 at 08:30 CET.
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the first patients have been included in a post-market ...
The Magle Group’s sponsorship of the SmiLe incubator is part of the Group’s commitment to supporting early-stage companies develop and comme...
Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 17 Maj 2022
The Magle Group today announces that it will commence its post market clinical study in collaboration with the University of Heidelberg, Med...
The Magle Group’s presence in Malmö is further strengthened by the signing of a pre-agreement to acquire land with the City of Malmö
Invitation to presentation of Magle Chemoswed’s report for Q1 2022
Magle Chemoswed Holding today reported financial results for the first quarter ended March 31, 2022, with solid profit growth year on year.
Magle Chemoswed Holding's Annual Report for 2021 has been published on the Group’s website as of today
Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till årsstämma tisdagen den 17 maj 2022.
Magle Chemoswed Holding AB enters into an agreement to appoint a liquidity provider to support the trading in the shares.
Magle Chemoswed Holding AB (publ) will publish its full-year report for 2021 on Friday 25 February 2022 at 08:30 CET.
Vid extra bolagsstämma i Magle Chemoswed Holding AB (publ) den 14 december 2021 som hölls genom poströstningsförfarande fattades i huvudsak ...
Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till extra bolagsstämma tisdagen den 14 december 2021.
Hedvig Lidgard Ström, a member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Board o...
Magle Chemoswed Holding today reported financial results for the third quarter ended September 30, 2021, which are in line with expectations...
Magle Chemoswed Holding is pleased to announce the appointment of Simon Jegou as Chief Strategy Officer of the Magle Chemoswed Holding Group...
Magle Chemoswed Holding AB (publ) will publish its quarterly report for Q3 2021 on Tuesday 16 November 2021 at 08:30 CET.
EmboCept® S is included in leading European guidelines for recommended therapeutic use
Magle Chemoswed establishes a manufacturing agreement with Oncopeptides
Magle Chemoswed announces confirmation of a large order of Isradipine for a new customer for delivery in the second quarter of 2022.
Västra Hamnen Corporate Finance has released a research update on Magle Chemoswed following the company's report for Q2 2021.
The second quarter of 2021 is in line with forecast with strong demand in the CDMO services and manufacturing.
Magle Chemoswed Holding AB (publ) will publish its quarterly report for Q2 2021 on Tuesday 17 August 2021 at 08:30 CET.
The addition of the patent application extends the protection of Magle Chemoswed’s technology platform and strengthens the future market pro...
Idag, den 18 maj 2021, hölls årsstämma i Magle Chemoswed Holding AB (publ).
The first quarter of 2021is in line with forecast and provides a strong performance basis for the remainder of 2021.
Invitation to presentation of Magle Chemoswed’s report for Q1 2021
Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till årsstämma tisdagen den 18 may 2021.
Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till extra bolagsstämma tisdagen den 18 may 2021.
The annual report for Magle Chemoswed Holding AB (publ) 2020 is released.
Greater market presence for technology products and innovations by adding PharmaCept’s strong European market presence and sales and marketi...
Good quarter despite COVID impact provides strong year end
